For 18 years, Truffle Capital has been creating and financing to success radical and disruptive innovations in two fields of expertise, Life Sciences and Information Technologies. These creations revolutionize their sectors and will become the tomorrow’s leaders.
Truffle Capital is the only European Fund to support its innovations from creation to commercial success.
Truffle Capital works closely with the world's best 50 universities to select and transform their most significant inventions into major technological innovations, novel medical devices and effective drug treatments.
In terms of Information technologies, Truffle Capital has focused in FinTechs since 2014. Thanks to its team of dedicated experts, Truffle is able to select products & services with underlying complex technologies (deep tech).
Discussion of Abivax Clinical Program involving Covid-19, Ulcerative Colitis, Crohn’s Disease and more
Hartmut Ehrlich and Philippe Pouletty discuss Abivax Pipeline of Clinical Programs involving Covid-19, Ulcerative Colitis, Crohn’s Disease...
Centers for Medicare & Medicaid Services (CMS) grant transitional pass-through (TPT) payment for Stryker's SpineJack® System
CMS announced the SpineJack implantable fracture reduction system qualified for the TPT payment as part of the 2021 Medicare Payment System.
Great article about Abivax : what makes it a unique candidate to treat Covid-19
In addition to its exciting results in ulcerative colitis...
Carbios strengthens its position as a reference shareholder in its subsidiary Carbiolice
The company created by Truffle acquired Limagrain Ingredients' position in Carbiolice, thus increasing its shareholding from 52% to 70%.
Abivax Turns Away Suitors as Lead Drug Starts Covid-19 Tests
Abivax, the French biotech embarking on tests of its lead experimental medicine for Covid-19, has turned away several suitors in recent months.
MEDEOR, Truffle Capital's new BioMedTech Fund, qualified by institutional investors through the Tibi committee
Medeor is among the 24 new funds qualified by the committee of institutional investors set up following the Tibi report.